Compare BCBP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | STTK |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 569.1M |
| IPO Year | 2005 | 2020 |
| Metric | BCBP | STTK |
|---|---|---|
| Price | $9.97 | $7.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $10.00 | $10.00 |
| AVG Volume (30 Days) | 95.4K | ★ 436.3K |
| Earning Date | 04-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $85.26 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.31 | $0.71 |
| 52 Week High | $10.25 | $8.33 |
| Indicator | BCBP | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 71.59 | 68.59 |
| Support Level | $7.55 | $1.85 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.30 | 0.51 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 76.82 | 65.79 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.